Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
Anne S. Reiner, Benjamin H. Durham, Mariko Yabe, Kseniya Petrova‐Drus, Jasmine H. Francis, Raajit K. Rampal, Mario E. Lacouture, Veronica Rotemberg, Omar Abdel‐Wahab, Katherine S. Panageas, Eli L. Diamond
Abstract
Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB-approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were interrupted after achieving complete or partial response by 18-fluorodeoxyglucose positron emission tomography (FDG-PET). 17/22 (77%) of patients experienced disease relapse following treatment interruption. Achieving a complete response prior to interruption, having a mutation other than BRAFV600E, and receiving MEK inhibition only were each associated with a statistically significant improvement in relapse-free survival. Relapse is common following treatment interruption however some patients may be suitable for limited-duration treatment.